



Plexxikon

**Jason Halladay, Ph.D.**

Vice President, Nonclinical Development



Dr. Jason Halladay has served as Vice President of Nonclinical Development since April 2020. His department integrates DMPK, preclinical and clinical pharmacology, toxicology, and pharmaceuticals and is responsible for the design and execution of translational strategy to bridge preclinical research and clinical studies. Dr. Halladay joined Plexxikon in 2017 to lead the DMPK and early formulation functions and strengthen the company's core competencies in small molecule drug discovery and development. Prior to Plexxikon, he was Director of DMPK at Anacor Pharmaceuticals. Dr. Halladay began his industry career at Theravance and Genentech, holding a series of positions with increasing responsibility for 13 years. He has a strong interest in drug metabolism, transporters, pharmacokinetics, and hypothesis-driven research to identify molecules with drug-like properties and progress them to the clinic. He is an author on 45 publications and was a contributing member of drug discovery teams leading to several NCEs entering human clinical trials. Dr. Halladay earned his undergraduate degree from Southern Utah University, and his Ph.D. degree in Pharmacology and Toxicology from the University of Arizona.